Mechanism of Osmanthus fragrans and its active component salidroside in improving hyperlipidemia
HU Yue, TIAN Engui, XIANG Wei, WANG Yingxin, HU Jiacheng, LIU Aijia, MAN Qiong, SHENG Yanmei
Affiliations
doi: 10.7501/j.issn.0253-2670.2026.14.018
文章导航
摘要
收起
目的 探讨桂花Osmanthus fragrans及其活性成分红景天苷改善高脂血症的作用机制。方法 采用油酸诱导法建立HepG2细胞脂质沉积模型，通过MTT实验及细胞内三酰甘油（triglyceride，TG）水平评价桂花醇提物及其成分毛蕊花糖苷、红景天苷、异类叶升麻苷、松果菊苷的调脂活性，并结合油红O染色法观察脂滴生成情况。采用高脂饲料喂养法建立高脂血症大鼠模型，设置对照组、模型组、桂花醇提物（810 mg/kg）组及红景天苷低、高剂量（40、80 mg/kg）组和辛伐他汀（2.1 mg/kg）组，每组8只，连续给药5周。检测各组大鼠血清脂质水平、肝脏指数及肝脏总胆固醇（total cholesterol，TC）、TG水平；油红O染色法观察各组肝脏脂质沉积情况；苏木素-伊红（hematoxylin-eosin，HE）染色法观察附睾脂肪组织病理形态；肝组织转录组测序法分析桂花醇提物改善高脂血症的潜在分子机制，并采用分子对接技术预测其主要活性成分红景天苷与细胞焦亡相关蛋白NOD样受体热蛋白结构域3（NOD like receptor family pyrin domain containing 3，NLRP3）、半胱氨酸天冬氨酸蛋白酶-1（cystein-asparate protease-1，Caspase-1）、消皮素D的N端片段（N-terminal fragment of gasdermin D，GSDMD-N）、白细胞介素-1β（interleukin-1β，IL-1β）、IL-18、IL-6的亲和力，进一步采用Western blotting验证红景天苷对肝组织中焦亡相关蛋白表达的影响。结果 桂花醇提物和红景天苷能显著降低油酸诱导的HepG2细胞内TG水平（P＜0.05、0.01、0.001），并减少脂滴积累；同时能显著降低模型大鼠血清TC、TG、低密度脂蛋白胆固醇（low density lipoprotein cholesterol，LDL-C）水平（P＜0.01、0.001），升高高密度脂蛋白胆固醇（high density lipoprotein cholesterol，HDL-C）水平（P＜0.001），并显著降低肝脏TC、TG水平（P＜0.01、0.001），减轻肝脏脂质沉积，改善脂肪组织病理形态。转录组学的基因本体（gene ontology，GO）及京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）富集分析结果提示桂花醇提物的调脂机制可能与调控脂质代谢和炎症反应有关。分子对接结果显示，红景天苷与NLRP3、Caspase-1、IL-1β等调控炎症反应的相关蛋白具有较高亲和力；Western blotting结果显示，与模型组比较，除红景天苷低剂量组肝组织中的剪切型Caspase-1（cleaved Caspase-1）外，其余各给药组焦亡相关蛋白表达水平均显著降低（P＜0.05、0.01、0.001）。结论 红景天苷可能是桂花改善高脂血症的主要活性成分之一，且其调脂机制与抑制NLRP3/Caspase-1/IL-1β信号通路抗细胞焦亡有关。
Objective To investigate the mechanism by which Osmanthus fragrans and its active component salidroside improve hyperlipidemia. Methods An oleic acid-induced lipid deposition model was established in HepG2 cells. Lipid-regulating activities of O. fragrans ethanol extract and its components (acteoside, salidroside, isoacteoside, echinacoside) were evaluated using MTT assay and intracellular triglyceride (TG) level, supplemented by oil red O staining to visualize lipid droplet formation. A hyperlipidemic rat model was established via high-fat diet feeding. Control group, model group, O. fragrans ethanol extract group (810 mg/kg), salidroside low-, high-dose (40, 80 mg/kg) groups and simvastatin (2.1 mg/kg) group were set up, with eight rats per group, drugs were continuously administration for five weeks. Serum lipid levels, hepatic index, hepatic total cholesterol (TC) and TG levels in rats of each group were measured. Oil red O staining was used to observe hepatic lipid deposition in each group. Hematoxylin-eosin (HE) staining was used to examine the pathological morphology of epididymal adipose tissue. Transcriptome sequencing of liver tissue was performed to analyze the potential molecular mechanisms by which O. fragrans ethanol extract ameliorates hyperlipidemia. Molecular docking technology was employed to predict the affinity of salidroside, the primary active component, with pyroptosis-related proteins NOD like receptor family pyrin domain containing 3 (NLRP3), cystein-asparate protease-1 (Caspase-1), N-terminal fragment of gasdermin D (GSDMD-N), interleukin-1β (IL-1β), IL-18 and IL-6. Western blotting was used to further validate the effect of salidroside on expressions of pyroptosis-related proteins in liver tissue. ResultsO. fragrans ethanol extract and salidroside significantly reduced TG levels (P < 0.05, 0.01, 0.001), and diminished lipid droplet accumulation in oleic acid-induced HepG2 cells. Concurrently, they markedly lowered TC, TG and low density lipoprotein cholesterol (LDL-C) levels in serum (P < 0.01, 0.001), increased high density lipoprotein cholesterol (HDL-C) level (P < 0.001), reduced hepatic TC and TG levels (P < 0.01, 0.001), alleviated liver lipid deposition, and improved adipose tissue pathology in model rats. Transcriptomic gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses suggested that the lipid-regulating mechanism of O. fragrans ethanol extract may be related to regulating lipid metabolism and inflammatory responses. Molecular docking results indicated that salidroside exhibits high affinity for proteins involved in regulating inflammatory responses, such as NLRP3, Caspase-1 and IL-1β. Western blotting results showed that compared with model group, except for the cleaved Caspase-1 in liver tissues of salidroside low-dose group, the expression levels of pyroptosis-related proteins were significantly reduced in all other treatment groups (P < 0.05, 0.01, 0.001). Conclusion Salidroside may be one of the primary active components in O. fragrans for improving hyperlipidemia, and its lipid-regulating mechanism is associated with inhibiting NLRP3/Caspase-1/IL-1β signaling pathway to counteract hepatic pyroptosis.
HU Yue, TIAN Engui, XIANG Wei, WANG Yingxin, HU Jiacheng, LIU Aijia, MAN Qiong, SHENG Yanmei.
Mechanism of Osmanthus fragrans and its active component salidroside in improving hyperlipidemia[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(14)
: 5565
-5578
.
DOI: 10.7501/j.issn.0253-2670.2026.14.018
El-Tantawy W H, Temraz A. Natural products for controlling hyperlipidemia: Review [J]. Arch Physiol Biochem, 2019, 125(2): 128-135. Zhao H W, Wang Y, Li Y Q, et al. Research advances in current drugs targeting hyperlipidemia (Review) [J]. Mol Med Rep, 2025, 32(4): 1-17. 王增武, 郭远林. 中国血脂管理指南(基层版2024年) [J]. 中国循环杂志, 2024, 39(04): 313-321. Hu H M, Wang S W, Chen C. Pathophysiological role and potential drug target of NLRP3 inflammasome in the metabolic disorders [J]. Cell Signal, 2024, 122: 111320. Sukhorukov V N, Orekhov A N. Molecular aspects of inflammation and lipid metabolism in health and disease: The role of the mitochondria [J]. Int J Mol Sci, 2024, 25(12): 6299. Ding P, Song Y M, Yang Y, et al. NLRP3 inflammasome and pyroptosis in cardiovascular diseases and exercise intervention [J]. Front Pharmacol, 2024, 15: 1368835. Ramachandran R, Manan A, Kim J, et al. NLRP3 inflammasome: A key player in the pathogenesis of life-style disorders [J]. Exp Mol Med, 2024, 56(7): 1488-1500. Zou J, Yan C Y, Wan J B. Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice [J]. Chin Med, 2022, 17(1): 17. 托力木吉·孟克其其格, 吴斌, 赵明芬. 中医药诊治高脂血症的研究进展[J]. 新疆中医药, 2023, 41(5): 134-137. Wang B J, Luan F, Bao Y W, et al. Traditional uses, phytochemical constituents and pharmacological properties of Osmanthus fragrans: A review [J]. J Ethnopharmacol, 2022, 293: 115273. 黄飞翔. 桂花醇提物对高脂血症小鼠血脂代谢紊乱的作用评价[D]. 成都: 成都医学院, 2025. 胡月, 黄飞翔, 樊炳, 等. 桂花乙醇提取物对高脂血症小鼠血脂异常与肠道菌群紊乱的改善作用[J]. 食品工业科技, 2026, 47(3): 403-411. 程芳, 张杰, 胡加成, 等. 基于网络药理学与动物实验探究桂花醇提物对慢性脑缺血神经损伤的保护作用及机制[J]. 中草药, 2023, 54(16): 5233-5243. Parafati M, La Russa D, Lascala A, et al. Dramatic suppression of lipogenesis and NO increase in beta-oxidation gene expression are among the key effects of bergamot flavonoids in fatty liver disease [J]. Antioxidants, 2024, 13(7): 766. Mangan M S J, Olhava E J, Roush W R, et al. Targeting the NLRP3 inflammasome in inflammatory diseases [J]. Nat Rev Drug Discov, 2018, 17(8): 588-606. 于宁, 宋囡, 贾连群, 等. 人参皂苷Rb1对高脂血症大鼠肝脏细胞焦亡的影响及其可能机制[J]. 中国病理生理杂志, 2019, 35(7): 1283-1288. Zhao X J, Yang Y Z, Zheng Y J, et al. Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-κB/NLRP3 inflammasome activation and lipid metabolism disorder [J]. Eur J Pharmacol, 2017, 809: 141-150. Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia [J]. Endokrynologia Polska, 2019, 70(6): 511-519. 刘迪, 刘阳, 郝珍飞, 等. 中药单体有效成分治疗高脂血症的研究进展[J]. 中国处方药, 2023, 21(4): 177-180. 裴帅, 曹宁宁, 李晓璇, 等. 中药干预高脂血症相关信号通路的研究进展[J]. 药物评价研究, 2022, 45(1): 177-185. Yang Z Y, Lu Y X, Li T T, et al. Osmanthus fragrans flavonoid extract inhibits adipogenesis and induces beiging in 3T3-L1 adipocytes [J]. Foods, 2024, 13(12): 1894. Tsai P J, Chang M L, Hsin C M, et al. Antilipotoxicity activity of Osmanthus fragrans and Chrysanthemum morifolium flower extracts in hepatocytes and renal glomerular mesangial cells [J]. Mediat Inflamm, 2017, 2017: 4856095. Yan Y M, Yang N X, Qin F L, et al. Echinacoside alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis via Nrf2/HMOX1 pathway [J]. Biomedicines, 2024, 12(12): 2728. 伊力亚斯·艾萨, 木塔力甫·艾买提, 任丽君, 等. 肉苁蓉活性成分毛蕊花糖苷通过诱导自噬对NAFLD的作用研究[J]. 现代医药卫生, 2025, 41(3): 577-583. 王笑妍, 李玫, 沈志纲, 等. 红景天苷药理作用研究进展[J]. 中成药, 2022, 44(12): 3932-3935. Meng J, Li Y, Sun F, et al. Salidroside alleviates LPS-induced liver injury and inflammation through SIRT1-NF-κB pathway and NLRP3 inflammasome [J]. Iran J Basic Med Sci, 2024, 27(3): 297-303. 王小刚, 赵娴, 李悦, 等. 高脂血症发病机制及治疗研究进展[J]. 辽宁中医药大学学报, 2020, 22(12): 196-200. Zhang Q, Fan X Y, Guo W L, et al. The protective mechanisms of macroalgae Laminaria japonica consumption against lipid metabolism disorders in high-fat diet-induced hyperlipidemic rats [J]. Food Funct, 2020, 11(4): 3256-3270. 郅果果, 穆杰, 邵冰杰, 等. 脂毒性在非酒精性脂肪性肝炎中的作用机制[J]. 临床肝胆病杂志, 2023, 39(7): 1681-1686. Meyers A K, Zhu X W. The NLRP3 inflammasome: Metabolic regulation and contribution to inflammaging [J]. Cells, 2020, 9(8): 1808. Zeng C, Wang R Q, Tan H M. Role of pyroptosis in cardiovascular diseases and its therapeutic implications [J]. Int J Biol Sci, 2019, 15(7): 1345-1357. Wang F, Yao W, Yu D X, et al. Protective role of thymoquinone in hyperlipidemia-induced liver injury in LDLR-/- mice [J]. BMC Gastroenterol, 2023, 23(1): 276. Yao Q Y, Liu J, Cui Q, et al. CCN1/integrin α5β1 instigates free fatty acid-induced hepatocyte lipid accumulation and pyroptosis through NLRP3 inflammasome activation [J]. Nutrients, 2022, 14(18): 3871. Yu L L, Hong W, Lu S, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: Therapeutic targets and treatment [J]. Front Pharmacol, 2022, 13: 780496. Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease [J]. Cardiovasc Diabetol, 2018, 17(1): 122.
PDF下载
全屏
22
7
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
